# University of Maryland sends cease-and-desist to Colorado > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/university-of-maryland-sends-cease-and-desist-to-colorado-cannabis-company-over-name-logo/ > **Published:** 2026-09-03T17:06:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:57-04:00 > **Clinical Summary:** Cannabis product authenticity remains a clinical concern. Learn how to counsel patients on safe sourcing and supply chain verification. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryResearchSafetyPainAnxietyMental Health Clinical Summary The University of Maryland issued a cease-and-desist letter to a Colorado cannabis company over alleged trademark infringement involving the university’s name and logo. This legal action reflects growing tensions between academic institutions and cannabis businesses operating in states where cannabis is legal, as companies may attempt to leverage recognizable institutional branding to enhance product credibility or market appeal. While the specific details of the infringement claim are not fully outlined in this summary, such disputes highlight the broader challenge of protecting institutional intellectual property in an expanding legal cannabis market. From a clinical perspective, this case underscores the importance of distinguishing between cannabis products marketed under legitimate institutional affiliations versus those misappropriating academic names, which could mislead patients about product quality, testing standards, or scientific endorsement. Clinicians should be cautious when patients reference cannabis products claiming university affiliation or endorsement and verify such claims directly with the institution before considering recommendations. Patients and providers should independently verify the legitimacy of cannabis product claims and avoid products that misrepresent institutional backing or scientific validation. Dr. Caplan’s Take “This is fundamentally a trademark and branding dispute rather than a clinical matter, but it does highlight how the cannabis industry is maturing and normalizing, which has both benefits and real risks when it comes to quality control and consumer safety standards.” Clinical Perspective 🏫 While this trademark dispute between an academic institution and a cannabis company may seem tangential to clinical care, it reflects the broader challenge clinicians face as cannabis products proliferate in increasingly commercialized markets with varying quality standards and marketing practices. The case underscores how cannabis industry growth has outpaced regulatory infrastructure, leaving healthcare providers with limited reliable information about product identity, potency, and safety—particularly when companies adopt names or logos that might confuse consumers about product origins or legitimacy. Clinicians should remain aware that patients may not always accurately identify which cannabis products they are using, either because they were misled by branding or because they obtained products through informal channels, complicating clinical history-taking and risk assessment. Given these naming and trademark uncertainties in the marketplace, providers should directly ask patients about specific product types, THC/CBD ratios, and source of purchase when taking a cannabis use history, rather than relying on patient recall of 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20University%20of%20Maryland%20sends%20cease-and-desist%20to%20Colorado%20cannabis%20company%20over%20name%2C%20logo%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75777)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75777)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20University%20of%20Maryland%20sends%20cease-and-desist%20to%20Colorado%20cannabis%20company%20over%20name%2C%20logo%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75777)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.fox5dc.com/news/university-maryland-sends-cease-and-desist-colorado-cannabis-company-over-name-logo](https://www.fox5dc.com/news/university-maryland-sends-cease-and-desist-colorado-cannabis-company-over-name-logo) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) #### 📄 Printable 1-Page Physician Patient Guide Download or print Dr. Benjamin Caplan’s official clinical reference guide to share with your healthcare team. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).